Literature DB >> 12948856

Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid.

Christopher J Fowler1, Kent-Olov Jonsson, Anna Andersson, Juha Juntunen, Tomi Järvinen, Séverine Vandevoorde, Didier M Lambert, Jeffrey C Jerman, Darren Smart.   

Abstract

It has previously been shown that the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG) inhibit the proliferation of C6 glioma cells in a manner that can be prevented by a combination of capsazepine (Caps) and cannabinoid (CB) receptor antagonists. It is not clear whether the effect of 2-AG is due to the compound itself, due to the rearrangement to form 1-arachidonoylglycerol (1-AG) or due to a metabolite. Here, it was found that the effects of 2-AG can be mimicked with 1-AG, both in terms of its potency and sensitivity to antagonism by Caps and CB receptor antagonists. In order to determine whether the effect of Caps could be ascribed to actions upon vanilloid receptors, the effect of a more selective vanilloid receptor antagonist, SB366791 was investigated. This compound inhibited capsaicin-induced Ca(2+) influx into rVR1-HEK293 cells with a pK(B) value of 6.8+/-0.3. The combination of SB366791 and CB receptor antagonists reduced the antiproliferative effect of 1-AG, confirming a vanilloid receptor component in its action. 1-AG, however, showed no direct effect on Ca(2+) influx into rVR1-HEK293 cells indicative of an indirect effect upon vanilloid receptors. Identification of the mechanism involved was hampered by a large inter-experimental variation in the sensitivity of the cells to the antiproliferative effects of 1-AG. A variation was also seen with anandamide, which was not a solubility issue, since its water soluble phosphate ester showed the same variability. In contrast, the sensitivity to methanandamide, which was not sensitive to antagonism by the combination of Caps and CB receptor antagonists, but has similar physicochemical properties to anandamide, did not vary between experiments. This variation greatly reduces the utility of these cells as a model system for the study of the antiproliferative effects of anandamide. Nevertheless, it was possible to conclude that the antiproliferative effects of anandamide were not solely mediated by either its hydrolysis to produce arachidonic acid or its CB receptor-mediated activation of phospholipase A(2) since palmitoyltrifluoromethyl ketone did not prevent the response to anandamide. The same result was seen with the fatty acid amide hydrolase inhibitor palmitoylethylamide. Increasing intracellular arachidonic acid by administration of arachidonic acid methyl ester did not affect cell proliferation, and the modest antiproliferative effect of umbelliferyl arachidonate was not prevented by a combination of Caps and CB receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12948856     DOI: 10.1016/s0006-2952(03)00392-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression.

Authors:  Markus Waldeck-Weiermair; Cristina Zoratti; Wolfgang F Graier; Karin Osibow; Nariman Balenga; Edith Goessnitzer; Maria Waldhoer; Roland Malli
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

2.  The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2.

Authors:  H A Patsos; D J Hicks; R R H Dobson; A Greenhough; N Woodman; J D Lane; A C Williams; C Paraskeva
Journal:  Gut       Date:  2005-08-11       Impact factor: 23.059

3.  TRPV1 regulators mediate gentamicin penetration of cultured kidney cells.

Authors:  Sigrid E Myrdal; Peter S Steyger
Journal:  Hear Res       Date:  2005-06       Impact factor: 3.208

4.  Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells.

Authors:  Chengzhi Xie; Guoxing Liu; Jiefeng Liu; Zhao Huang; Fusheng Wang; Xiaohua Lei; Xiaolong Wu; Shengfu Huang; Dewu Zhong; Xundi Xu
Journal:  Oncol Lett       Date:  2012-06-11       Impact factor: 2.967

Review 5.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

6.  A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.

Authors:  Koppany Visnyei; Hideyuki Onodera; Robert Damoiseaux; Kuniyasu Saigusa; Syuzanna Petrosyan; David De Vries; Denise Ferrari; Jonathan Saxe; Eduard H Panosyan; Michael Masterman-Smith; Jack Mottahedeh; Kenneth A Bradley; Jing Huang; Chiara Sabatti; Ichiro Nakano; Harley I Kornblum
Journal:  Mol Cancer Ther       Date:  2011-08-22       Impact factor: 6.261

Review 7.  Insights into the effects of the endocannabinoid system in cancer: a review.

Authors:  Ana Isabel Fraguas-Sánchez; Cristina Martín-Sabroso; Ana Isabel Torres-Suárez
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

Review 8.  Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.

Authors:  Nephi Stella
Journal:  Glia       Date:  2010-07       Impact factor: 7.452

Review 9.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

Review 10.  Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas.

Authors:  Francisco Carlos Machado Rocha; Jair Guilherme Dos Santos Júnior; Sergio Carlos Stefano; Dartiu Xavier da Silveira
Journal:  J Neurooncol       Date:  2013-10-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.